Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

469 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
siRNA screen identifies QPCT as a druggable target for Huntington's disease.
Jimenez-Sanchez M, Lam W, Hannus M, Sönnichsen B, Imarisio S, Fleming A, Tarditi A, Menzies F, Dami TE, Xu C, Gonzalez-Couto E, Lazzeroni G, Heitz F, Diamanti D, Massai L, Satagopam VP, Marconi G, Caramelli C, Nencini A, Andreini M, Sardone GL, Caradonna NP, Porcari V, Scali C, Schneider R, Pollio G, O'Kane CJ, Caricasole A, Rubinsztein DC. Jimenez-Sanchez M, et al. Among authors: heitz f. Nat Chem Biol. 2015 May;11(5):347-354. doi: 10.1038/nchembio.1790. Epub 2015 Apr 6. Nat Chem Biol. 2015. PMID: 25848931 Free PMC article.
Fused 3-Hydroxy-3-trifluoromethylpyrazoles Inhibit Mutant Huntingtin Toxicity.
La Rosa S, Benicchi T, Bettinetti L, Ceccarelli I, Diodato E, Federico C, Fiengo P, Franceschini D, Gokce O, Heitz F, Lazzeroni G, Luthi-Carter R, Magnoni L, Miragliotta V, Scali C, Valacchi M. La Rosa S, et al. Among authors: heitz f. ACS Med Chem Lett. 2013 Aug 8;4(10):979-84. doi: 10.1021/ml400251g. eCollection 2013 Oct 10. ACS Med Chem Lett. 2013. PMID: 24900595 Free PMC article.
Small molecule drug discovery for Huntington's Disease.
Fecke W, Gianfriddo M, Gaviraghi G, Terstappen GC, Heitz F. Fecke W, et al. Among authors: heitz f. Drug Discov Today. 2009 May;14(9-10):453-64. doi: 10.1016/j.drudis.2009.02.006. Epub 2009 Feb 25. Drug Discov Today. 2009. PMID: 19429504 Review.
Design, synthesis and biological activity of original pyrazolo-pyrido-diazepine, -pyrazine and -oxazine dione derivatives as novel dual Nox4/Nox1 inhibitors.
Gaggini F, Laleu B, Orchard M, Fioraso-Cartier L, Cagnon L, Houngninou-Molango S, Gradia A, Duboux G, Merlot C, Heitz F, Szyndralewiez C, Page P. Gaggini F, et al. Among authors: heitz f. Bioorg Med Chem. 2011 Dec 1;19(23):6989-99. doi: 10.1016/j.bmc.2011.10.016. Epub 2011 Oct 17. Bioorg Med Chem. 2011. PMID: 22041175
Therapeutic potential of NADPH oxidase 1/4 inhibitors.
Teixeira G, Szyndralewiez C, Molango S, Carnesecchi S, Heitz F, Wiesel P, Wood JM. Teixeira G, et al. Among authors: heitz f. Br J Pharmacol. 2017 Jun;174(12):1647-1669. doi: 10.1111/bph.13532. Epub 2016 Jul 14. Br J Pharmacol. 2017. PMID: 27273790 Free PMC article. Review.
Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy.
Jha JC, Gray SP, Barit D, Okabe J, El-Osta A, Namikoshi T, Thallas-Bonke V, Wingler K, Szyndralewiez C, Heitz F, Touyz RM, Cooper ME, Schmidt HH, Jandeleit-Dahm KA. Jha JC, et al. Among authors: heitz f. J Am Soc Nephrol. 2014 Jun;25(6):1237-54. doi: 10.1681/ASN.2013070810. Epub 2014 Feb 7. J Am Soc Nephrol. 2014. PMID: 24511132 Free PMC article.
469 results